新闻中心

NEWS

/
Social responsibility
Hefei Huafang Pharmaceutical Technology Co., Ltd. undertakes the emergency research project of epidemic prevention in Hefei (the first batch)

Hefei Huafang Pharmaceutical Technology Co., Ltd. undertakes the emergency research project of epidemic prevention in Hefei (the first batch)

2020-03-23
In December 2019, a new type of coronavirus (2019 Novel Coronavirus, 2019-nCoV) infection appeared in Wuhan City, Hubei Province. Similar cases. At present, the National Health Commission has received reports from 31 provinces (autonomous regions, municipalities directly under the central government) and the Xinjiang Production and Construction Corps, with a total of more than 80,000 confirmed cases and more than 3,000 deaths, with a case fatality rate of about 3.7%. There is still no specific treatment for the novel coronavirus pneumonia. Early diagnosis and timely development of specific drugs are the key to preventing the spread of the epidemic. On February 18, 2020, the Guangdong provincial government held a regular press conference on epidemic prevention and control. Zhong Nanshan, an academician of the Chinese Academy of Engineering, attended the conference and reported the latest progress in drug research for the treatment of new coronaviruses. Academician Zhong Nanshan said that there is a process for Western medicine to enter the human body, but Chinese medicine is different. In this anti-epidemic process, the first batch of traditional Chinese medicines used include Liushen Pills, Lianhua Qingwen Capsules, Jinzhen Oral Liquid, Reduning Injection, etc. These traditional Chinese medicines have been used in general clinical practice for many years.

More

Previous page
1
2
5

Huafang Pharmceutical Sciences

Hotline:0551-65551391

Fax:0551-65336396

Add: Building D-5, Technology Industrial Park, 168 Xiangzhang Avenue, National High-tech Zone, Hefei City

Huafang

Wechat

Huafang

Mobile

Copyright © Huafang Pharmceutical